Literature DB >> 6684933

Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man.

H Laufen, M Aumann, M Leitold.   

Abstract

The plasma concentrations of isosorbide dinitrate (ISDN) and its two pharmacologically active metabolites isosorbide 2-mononitrate (IS-2-MN) and isosorbide 5-mononitrate (IS-5-MN) were determined after oral administration of 20 mg ISDN and 20 mg of each of the mononitrates. The mean concentration-time curve of ISDN showed a peak of 51.6 ng/ml 15 min after drug intake, and declined bi-exponentially with a terminal half-life of 36.5 min. The mean concentrations of the simultaneously measured metabolic products IS-2-MN and IS-5-MN reached a maximum of 40.5 ng/ml and 144.4 ng/ml, respectively. In contrast, after the direct ingestion of isosorbide mononitrates, peaks of 409.1 ng/ml (IS-2-MN) and 483.2 ng/ml (IS-5-MN) were observed in the corresponding mean curves. Mean half-lives of 1.72 h for IS-2-MN and 4.20 h for IS-5-MN were calculated. The mean apparent volumes of distribution were 44.5 l (IS-2-MN) and 34.4 l (IS-5-MN), suggesting that the isosorbide mononitrates are distributed throughout the whole body fluid. After ISDN administration, it was estimated that 3.0 mg IS-2-MN and 7.8 mg IS-5-MN reached the systemic circulation. This corresponds to 63% of the ISDN dose being converted to isosorbide mononitrates by metabolic processes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6684933

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  8 in total

1.  The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect.

Authors:  A J Jackson
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

2.  The effect of food on the oral absorption of isosorbide-5-mononitrate.

Authors:  H Laufen; M Leitold
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

3.  Pharmacokinetics of oral glycerol-1-nitrate.

Authors:  H Laufen; M Leitold; R A Yeates
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Pharmacokinetics of isosorbide-5-nitrate during haemodialysis and peritoneal dialysis.

Authors:  J Evers; R Bonn; A Boertz; W Cawello; V Luckow; M Fey; F Aboudan; H A Dickmans
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion.

Authors:  Y Santoni; A Iliadis; J P Cano; R Luccioni; Y Frances
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

6.  Pharmacokinetics of isosorbide-5-nitrate in renal failure.

Authors:  J Evers; B Krakamp; W Klimkait; H A Dickmans; J Maddock; V Luckow; W Cawello; M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Isosorbide dinitrate in plasma and dialysate during haemodialysis.

Authors:  H Bauer; H Laufen; H E Franz
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Isosorbide-5-nitrate sustained-release pellets - an example of computer-supported drug development.

Authors:  H Zerbe; V Luckow; W Cawello; G Cordes
Journal:  Pharm Res       Date:  1985-01       Impact factor: 4.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.